Previous Article | Next Article ![]()
Molecular and Cellular Biology, June 2004, p. 5421-5433, Vol. 24, No. 12
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.12.5421-5433.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107,1 Department of Molecular Biology of the Cell II, German Cancer Research Center, D-69120 Heidelberg, Germany2
Received 6 January 2004/ Returned for modification 4 February 2004/ Accepted 24 March 2004
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
In many hemopoietic cell lines, the induction of differentiation is preceded by a period of vigorous cell proliferation, and it has been suggested that this period of cell proliferation is necessary for differentiation to occur (65, 71). It seems that, in hemopoietic cells, certain growth factors send both proliferation and differentiation signals (38), with the latter eventually prevailing. Therefore, at least in certain cell types, a third component may be necessary for sustained cell proliferationi.e., the extinction of a differentiation program. This hypothesis is not novel. For years, a number of investigators have proposed that a block in differentiation is a sine qua non for the development of malignancy, particularly in hemopoietic tumors (14, 24, 42, 43, 54, 60). Indeed, the use of retinoic acid for some forms of leukemia has been referred to as a differentiation therapy (6). This situation has been elegantly summarized by Gilliland and Tallman (14), who proposed two classes of mutations in acute leukemia: one class of mutations confers a proliferative advantage, while a second class of mutations impairs hemopoietic differentiation.
The respective roles of proliferation and differentiation in determining the fate of hemopoietic cells are well illustrated for 32D murine myeloid cells. 32D cells require interleukin-3 (IL-3) for growth and rapidly undergo apoptosis after the withdrawal of IL-3 (65, 74). Parental 32D cells have very low levels of the type 1 insulin-like growth factor I (IGF-I) receptor (IGF-IR) and do not express insulin receptor substrate (IRS) 1 (IRS-1) or IRS-2 (64, 70, 73), the main docking protein of both the IGF-IR and the insulin receptor (72). 32D cells expressing moderate levels of a human IGF-IR (32D IGF-IR cells) survive in the absence of IL-3 and, with the addition of IGF-I, grow vigorously for about 48 h (64). After 48 to 72 h, 32D IGF-IR cells begin to differentiate along the granulocytic pathway (64). This action is not surprising, as IGF-I can induce differentiation in other hemopoietic cell lines besides the 32D cell line (1, 32). When 32D IGF-IR cells are stably transfected with a plasmid expressing IRS-1 (32D IGF-IR/IRS-1 cells), the cells no longer differentiate, grow indefinitely in the absence of IL-3, and even form tumors in mice (63). We interpret these results as indicating that in 32D cells, the activated IGF-IR, like other growth factor receptors of hemopoietic cells, sends signals for both proliferation and differentiation. When the cells express IRS-1, proliferation prevails, while in its absence, the cells differentiate. The antidifferentiation signal from IRS-1 is indirectly supported by the observation that cell types prone to differentiation often do not express IRS-1 or express very small amounts (25, 36, 53, 59, 70).
IRS-1 also plays a major role in the regulation of cell and body size. Drosophila has a receptor that partakes of both the IGF-IR and the IR and has homologues of the IRS proteins phosphatidylinositol 3-kinase, Akt, and S6K1. All of these homologues regulate cell and body size in Drosophila (4, 30, 35, 66). For instance, deletion of the Drosophila IRS homologue chico reduces fly weight by 65% in females and 55% in males. The reduction in body and organ size is due to a reduction in both cell number and cell size. Mice with a targeted disruption of the IRS-1 (45) or S6K1 (57) gene are smaller than their wild-type littermates. Similarly, 32D cells expressing IRS-1 are twice as large as 32D cells not expressing IRS-1, even when both cell types are growing exponentially (63). The recent reports that IRS-1 can translocate to the nucleus and bind UBF1 (58, 62) provide a molecular explanation for the effect of IRS-1 on cell and body size. During differentiation (which is inhibited by IRS-1), an inhibition of RNA polymerase I activity (10, 11, 28, 61) and a decrease in cell size (63) occur. In terminally differentiated cells, UBF1 is no longer detectable (11, 61), and the nucleolus (which is the site of rRNA synthesis) involutes (50).
As indicated above, PES1 is involved in both ribosome biogenesis and DNA replication, while UBF1 is one of the regulators of RNA polymerase I activity. Our hypothesis is that 32D-derived cells require three different signals from the activated IGF-IR for sustained cell proliferation: an increase in cell size, the activation of the cell cycle program, and the extinction of a differentiation program. To test this hypothesis, we examined whether PES1 and UBF1 can make 32D IGF-IR cells IL-3 independent, like IRS-1 does. We found that both PES1 and UBF1 cause an increase in cell size, that PES1 alters the cell cycle distribution, but that neither of them can inhibit the differentiation program and make 32D IGF-IR cells grow indefinitely in medium deprived of IL-3 and supplemented with IGF-1. The results were different for two cell lines of untransformed mouse embryo fibroblasts (MEFs) that express substantial levels of IRS-1 and are therefore refractory to differentiation. In these cells, both PES1 and UBF1 cause cellular transformation, as measured by the ability to form colonies in soft agar. We suggest that, with regard to IGF-IR signaling in 32D cells, extinction of the differentiation program is a requirement for sustained cell proliferation. This suggestion is in agreement with the hypothesis mentioned above that in certain forms of leukemia, both a stimulation of proliferation and a block of differentiation are necessary for tumor development. In this respect, our experiments simply provide a molecularly defined model for the respective roles of proliferation and differentiation in the growth of a myeloid cell line that can either differentiate or be transformed into a tumor-forming cell line (63).
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell lines. The cell lines used were 32D clone 3 (65), 32D IGF-IR (63), and 32D IGF-IR/IRS-1 (64). In one experiment, we also used 32D IRS-1 cells (74), which are parental 32D cells expressing IRS-1. 32D and 32D-derived cells were grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Life Technologies, Inc.), 10% WEHI cell-conditioned medium as a source of IL-3, and the antibiotic required for selection: 250 µg of G418 (Life Technologies)/ml or 250 µg of hygromycin (Calbiochem)/ml.
32D, 32D IGF-IR, 32D IGF-IR/IRS-1, and 32D IRS-1 cells were transduced (46) with the MSCVpuro FLAG/UBF1 and MSCVpuro PES1/FLAG retroviral vectors. Mixed populations were selected with 1.5 µg of puromycin/ml to generate the various cell lines described below.
In other experiments, we used as MEFs R12 and R508 cells. Both of these cell lines were derived from R cells, which are MEFs originating from mouse embryos with a targeted disruption of the IGF-IR genes (56). R12 and R508 cells were generated by transfection with a plasmid expressing human IGF-IR. R12 cells express 3 x 103 IGF-IRs/cell, while R508 cells express 15 x 103 receptors/cell (52). Both of these cell lines do not respond to IGF-I with proliferation and do not form colonies in soft agar (49, 52). They were transduced with the same retroviral vectors and selected with the same procedures as 32D cells as described above.
Growth curves. Cells exponentially growing in IL-3 were washed three times with Hanks balanced salt solution (HBSS) and seeded at a density of 5 x 104 cells/35-mm plate containing 2 ml of RPMI 1640 medium supplemented with 10% FBS, no IGF-I or IGF-I at 50 ng/ml (GIBCO BRL), or 10% WEHI cell-conditioned medium as the source of IL-3. Cells were counted by trypan blue exclusion (Life Technologies) at various times after IL-3 withdrawal.
Northern blotting. Exponentially growing cells were washed three times with HBSS and seeded at 5 x 104 cells/ml in RPMI 1640 medium supplemented with 10% FBS, IGF-I at 50 ng/ml, 10% WEHI cell-conditioned medium, or granulocyte colony-stimulating factor at 25 ng/ml (BD Biosciences Pharmingen). At various times, cells were collected and total RNA was extracted with an RNeasy minikit (Qiagen). A total of 8 µg of total RNA for each sample was run on a 1% agarose formaldehyde gel, blotted onto a nylon membrane, and hybridized with 24p3 cDNA (46) or myeloperoxidase (MPO) cDNA (47).
Western blotting and immunoprecipitation. Cells seeded under the same conditions as those used for Northern blotting were harvested at various times, washed with cold phosphate-buffered saline (PBS), and lysed in 50 mM HEPES (pH 7.5)-150 mM NaCl-1.5 mM MgCl2-1 mM EGTA-10% glycerol-1% NP-40-100 mM NaF-10 mM sodium pyrophosphate-0.2 mM sodium orthovanadate-1 mM phenylmethylsulfonyl fluoride-10 µg of aprotinin/ml. The rest of the procedure was the same as that described in detail in previous reports (39, 47). The following antibodies were used: anti-IRS-1 C-20 and anti-ID2 (Santa Cruz Biotechnology, Santa Cruz, Calif.), anti-FLAG M2-peroxidase conjugate A-8592 and EZview red anti-FLAG M2 affinity gel F2426 (Sigma), anti-pescadillo rabbit polyclonal antibody (Bethyl Laboratories, Inc.), anti-glyceraldehyde-3-phosphate dehydrogenase (Research Diagnostics, Inc.), and anti-Grb2 (Transduction Laboratories).
FACS analysis. Exponentially growing cells were washed with HBSS and seeded at 5 x 104 cells/ml in RPMI 1640 medium supplemented with 10% FBS, IGF-I at 50 ng/ml, or 10% WEHI cell-conditioned medium. After 24 h, the cells were washed with cold PBS and analyzed by fluorescence-activated cell sorting (FACS) for cell size (63). For cell cycle distribution, cells were fixed in 70% ethanol for 2 h on ice and then washed with PBS. Cells were suspended in propidium iodide-Triton X-100 staining solution with RNase A and analyzed after 30 min. For bromodeoxyuridine (BrdU) labeling, cells were incubated with BrdU for 1 h by using a BrdU flow kit (BD Biosciences Pharmingen) following the manufacturer's protocol. FACS analysis was carried out by using a Beckman Coulter XL four-color analyzer with an argon ion 488-nm laser (Beckman Coulter Corporation, Hialeah, Fla.).
Morphological analysis. For analysis of differentiation, exponentially growing cells were collected, washed three times with HBSS, and seeded at 5 x 104 cells/ml in RPMI 1640 medium containing 10% FBS and 50 ng of IGF-I/ml. At various times, viable cells were counted by trypan blue exclusion (Life Technologies), and cytospin samples were used for morphological analysis as described by Valentinis et al. (64).
Confocal microscopy. Cells plated on glass coverslips were washed with PBS and fixed with 3.0% paraformaldehyde in PBS for 20 min at room temperature, followed by permeabilization with 0.2% Triton X-100 in PBS for 2 min at room temperature. Coverslips were washed with PBS and blocked in 10% normal donkey serum (sc-2044; Santa Cruz Biotechnology) in PBS for 20 min at room temperature. Coverslips were washed with PBS and incubated for 1 h at room temperature with anti-FLAG-fluorescein isothiocyanate-conjugated F4049 (Sigma) antibody. After being washed with PBS, coverslips were digested with RNase A (1 mg/ml) for 30 min and then stained with propidium iodide (2.5 µg/ml; P-3566; Molecular Probes) for 5 min. Finally, coverslips were washed with PBS three times and mounted on glass slides with Vectashield mounting medium (H-1000; Vector Laboratories Inc.). Fluorescent images were collected by using a Zeiss Axiovert 100 confocal microscope with a Zeiss x40 objective.
Statistical analysis. Statistical significance (P < 0.05) between two measurements and among multiple groups was determined with the two-tailed Student t test analysis of variance and with the Bonferroni method, respectively (44).
| RESULTS |
|---|
|
|
|---|
|
|
Parental 32D cells died even in the presence of IGF-I, as expected, and the expression in these cells of either UBF1 or PES1 had very little effect on their survival. At the end of 24 h, a few more of these cells than of parental 32D cells were alive, but all cells had died by 48 h in all three cell lines (data not shown). We also infected with the same retroviruses 32D IRS-1 cells, which do not survive the shift from IL-3 to IGF-I (74). Neither PES1 not UBF1 protected these cells from apoptosis (data not shown). These experiments indicate that, unlike IRS-1, neither PES1 nor UBF1 can sustain the proliferation of 32D IGF-IR cells when the cells are shifted from IL-3 to IGF-I. PES1 has a modest positive effect on the growth of 32D IGF-IR/IRS-1 cells.
We therefore set out to investigate the mechanism(s) behind the failure of PES1 and UBF1 to sustain the growth of 32D IGF-IR cells.
Cell cycle distribution (DNA amounts). Because PES1 is known to affect DNA synthesis, besides ribosome biogenesis (12, 26, 31), and also to slightly increase the growth of 32D IGF-IR/IRS-1 cells (Fig. 2), we examined whether it would alter cell cycle distribution. UBF1 has not been reported to affect DNA synthesis, and we did not expect it to affect cell cycle distribution. To determine the cell cycle distributions of various cell lines by FACS analysis (see Methods and Materials), we examined them 24 h after a shift from IL-3 to IGF-1. At this time, all cell lines were growing exponentially and at similar rates (Fig. 2), so that FACS analysis provides the cell cycle distributions of cell populations in which close to 100% of the cells are dividing (44). 32D IGF-IR cells and 32D IGF-IR/IRS-1 cells, whether expressing UBF1 or not, had the usual cell cycle distributions, with about 45% of cells in G1 phase, 35% in S phase, and 20% in G2 phase. Dramatically different results were obtained with cells expressing PES1: the percentage of cells in S phase was only 18%, while there was an accumulation of cells in the G2 peak (4N DNA) to as much as 47% (Fig. 3A). This was true whether PES1 was expressed in 32D IGF-IR or 32D IGF-IR/IRS-1 cells (Fig. 3A). This experiment was repeated with four different samples at 24 and 48 h, with similar results. This anomalous distribution seemed to be dependent on IGF-1 for two reasons. First, 32D cells expressing PES1 died even in the presence of IGF-1, and second, the abnormal S phase was hardly detectable in the same cells in the presence of IL-3. There was a slight tendency for an increase in the number of cells in the G2 peak even in the presence of IL-3 (data not shown), but this increase probably would have passed unnoticed without the dramatic results obtained when the cells were grown in IGF-1.
|
To confirm the decrease in the number of exponentially growing 32D-derived cells expressing PES1 in S phase, we labeled the cells with BrdU 24 h after a shift from IL-3 to IGF-I. The cells were labeled for 1 h, so that the fraction of labeled cells would include those that were synthesizing DNA when BrdU was added and those that entered S phase during the 1-h labeling. The results are summarized in Fig. 3B. UBF1 expression had little or no effect on the percentage of cells labeled by BrdU, but PES1 expression markedly decreased it. This finding was especially evident in 32D IGF-IR cells, where the expression of PES1 decreased the percentage of cells labeled by BrdU from 58 to 32%. At this time after a shift to IGF-1, all cell lines, except for the parental 32D cell line, are growing exponentially with about the same doubling times (44; see below). The decrease in the percentage of cells in S phase therefore is compatible with a shortening of S phase and a lengthening of G2 phase.
Cell size. We next examined whether the overexpression of PES1 and UBF1 would alter cell size. Both UBF1 (16) and PES1 (12, 31) play an important role in ribosome biogenesis, which determines cell size (16, 23, 37). The expression of UBF1 in cardiomyocytes increases cell size (17). IRS-1, which binds to UBF1 (58, 62), also increases cell size, both in cells in cultures (63) and in animals (4, 45). Since parental 32D cells do not survive in the absence of IL-3, these experiments were carried out with cells growing in IL-3. The results of a representative experiment are shown in Fig. 4, where cell size was determined by FACS analysis. Both UBF1 and PES1 increased cell size, about as well as if not better than IRS-1. The increase was most dramatic in parental 32D cells, where both UBF1 and PES1 doubled the mean size of cells. The increase was less dramatic in 32D IGF-IR and 32D IGF-IR/IRS-1 cells, although it was significant and reproducible. In the last two cell lines, UBF1 and PES1 increased cell size by about 20 to 25%. Additional data on cell size are given below.
|
|
|
We next studied the PES1-IRS-1 interaction by coimmunoprecipitation. Lysates were prepared and immunoprecipitated with an anti-FLAG antibody (which recognizes only exogenous PES1). Figure 7B shows that the anti-FLAG antibody immunoprecipitated IRS-1 in 32D IGF-IR/IRS-1 cells (the other two cell lines were used as controls not expressing IRS-1). The FLAG-tagged protein, though, was also visible in 32D IGF-IR cells expressing PES1 (Fig. 7B). We also studied the interaction between PES1 and UBF1. In lysates of cells expressing the FLAG-tagged PES1 construct, immunoprecipitation with an anti-FLAG antibody caused the appearance of UBF1 in the immunoprecipitate (Fig. 7C). Two negative controls were used. In one control experiment, lysates from cells not expressing the FLAG-tagged PES1 construct were immunoprecipitated with the anti-FLAG antibody. No IRS-1 was detected in the immunoprecipitate. In the second control experiment, we immunoprecipitated with the anti-FLAG antibody FLAG-tagged mutant IRS-1 (46) that does not localize to nuclei (deletion of the PHPTB domain). We could not detect endogenous PES1 in the immunoprecipitate (data not shown). It seems, therefore, that UBF1, IRS-1, and PES1 all can colocalize to nucleoli, where they may form a large complex cooperating in the activation of the ribosomal DNA promoter (16).
|
|
Effect of PES1 and UBF1 on the growth of MEFs. The results obtained thus far seem to suggest that both UBF1 and PES1 increase cell size and may affect cell proliferation but fail to make 32D-derived cells IL-3 independent. The results also suggest that PES1 and UBF1 cannot inhibit in 32D-derived cells the differentiation program initiated by IGF-IR (in cells that do not express IRS-1). If this suggestion is correct, then both UBF1 and PES1 should be able to transform MEFs that express IRS-1 and are known not to differentiate. For this purpose, we tested the effect of the ectopic expression of PES1 and UBF1 in MEFs that have substantial levels of IRS-1. We selected for this purpose R12 and R508 cells; these cells are derived from R cells, which are MEFs originating from mouse embryos with a targeted disruption of the IGF-IR genes (34). Human IGF-IR was introduced into R12 and R508 cells to produce cell lines that express, respectively, 3 x 103 and 15 x 103 IGF-IRs/cell (52). R12 and R508 cells do not respond to IGF-I with proliferation, although they do respond to IGF-I with autophosphorylation of the receptor and modest tyrosyl phosphorylation of IRS-1 (49). Neither of these cell lines can form colonies in soft agar. We engineered both of these cell lines to express UBF1 or PES1 (see Methods and Materials), and we tested them for their ability to form colonies in soft agar. The results are shown in Fig. 9A, from which it is evident that both PES1 and UBF1 increased colony formation in soft agar of both R12 and R508 cells. As in previous experiments, parental R12 and R508 cells generated very few colonies in soft agar (averages of fewer than 1 in R12 cells and 2.5 in R508 cells). PES1 increased the number of colonies to 120 or more, while UBF1 increased the number of colonies to 70 to 110 per plate. Interestingly, the addition of IGF-I had no effect on R12 cells, while a small effect was noted for R508 cells. This finding is in agreement with previous reports indicating that R508 cells are slightly more sensitive to IGF-I than R12 cells (49, 52). Figure 9B shows the levels of expression of exogenous PES1 and UBF1 in MEFs.
|
| DISCUSSION |
|---|
|
|
|---|
First, we show that in 32D-derived cells, both UBF1 and PES1 can increase cell size, at least as well as IRS-1. Their effect on 32D cell size is evident in diverse growth conditions and is maintained even in differentiated cells. Second, PES1 alters the cell cycle distribution in exponentially growing 32D IGF-IR and 32D IGF-IR/IRS-1 cells and also slightly increases cell proliferation in the latter cell line. Third, despite their effect on cell size (and, for PES, on the cell cycle), neither of them can sustain the proliferation of 32D IGF-IR cells in the presence of IGF-I but in the absence of IL-3. 32D IGF-IR cells expressing PES1 or UBF1 stop growing, like their parental cells, after about 48 h. Their failure to grow further is accompanied by a failure to inhibit the IGF-I-mediated induction of differentiation, induction that is instead blocked by IRS-1 (63; this study). Fourth, however, PES1 and UBF1 transform (colony formation in soft agar) MEFs that do not have a differentiation program. These points are considered separately.
We selected PES1 and UBF1 because both of them play a role in ribosome biogenesis (12, 16, 31), which determines cell size (23, 37). IRS-1 also increases cell size (4, 69), and it may do so by binding and presumably activating UBF1 (58, 62). In addition, PES1 is also involved in DNA replication (12), thus connecting the increase in cell size with the cell cycle program, a requirement for normal cell division (13, 19). Our results confirm that PES1 and UBF1 can increase cell size. This finding was demonstrated by FACS analysis and by morphological observations. Neither PES1 nor UBF1 requires IRS-1 to increase cell size, as they increase cell size in 32D IGF-IR cells and parental 32D cells, which do not express IRS-1 (64, 70). This finding is compatible with the data in the literature (see above) indicating that IGF-IR and IRS-1 regulate, in a nonredundant way, only about 50% of cell size. The other 50% is IRS-1 independent.
PES1 is also known to affect DNA replication (12, 31), and our results are compatible with its role in this process. Exponentially growing cells had an altered cell cycle distribution, with a shortening of S phase and a lengthening of G2 phase, which resulted in overall growth in the first 48 h that was only slightly increased over that of parental cells. Interestingly, the effect of PES1 in these cells apparently is dependent on the activation of IGF-IR signaling. Cells growing in IL-3 do not seem to show the same dramatic changes in cell cycle distribution that are caused by the overexpression of PES1. A reasonable question at this point is whether cells in the G2 peak are truly in G2. Since at 24 h all cell lines are growing exponentially, with 98 to 99% of the cells in the cell cycle (44), FACS analysis ought to provide a true cell cycle distribution. This distribution persists at 6 days after a shift to IGF-I, by which time 32D IGF-IR cells are differentiated (the only exception being IRS-1-expressing cells). At 6 days, therefore, it would be meaningless to discuss a G2 phase; at that time, FACS analysis simply measures DNA amounts. It is intriguing that 32D IGF-IR cells expressing PES1 and UBF1 remain very large even when differentiated. Brown et al. (5) reported that HL60 cells halted in G1 or S phase differentiate normally. Morphological analysis of size in differentiated cells (6 days after a shift to IGF-I) was confirmed by FACS analysis (data not shown).
The most important conclusion of our experiments is that, of the three proteins that increase cell size (and, for PES1, also affect DNA replication), only IRS-1 can induce sustained cell proliferation in 32D IGF-IR cells. As mentioned above, 32D IGF-IR/IRS-1 cells not only are IL-3 independent but also actually form tumors in mice, something that parental 32D cells and 32D IGF-IR cells cannot do (63). The failure of UBF1 and PES1 to sustain IGF-1-dependent cell proliferation is accompanied by the differentiation of cells into granulocytes, as in parental 32D IGF-IR cells.
The differentiation of 32D IGF-IR cells, parental or overexpressing PES1 or UBF1, is documented unequivocally by morphological analysis, as they become granulocytes. It is confirmed by their inability to extinguish markers of differentiation that occur within the first 24 h after a shift to IGF-I, when 32D IGF-IR cells are still growing (44). These markers are MPO (47, 64) and 24p3 (46, 55) mRNAs and ID proteins. The ID proteins, especially ID1 and ID2, are strong inhibitors of differentiation (3, 27, 51). In 32D IGF-IR cells, ID2 gene expression is very low, almost undetectable. Ectopic expression of IRS-1 in these cells causes a dramatic increase in ID2 gene expression (2, 40, 47; this study). Neither UBF1 nor PES1 is capable of inducing ID2 expression in 32D IGF-IR cells.
A model to explain these results could be based on the hypothesis that PES1, UBF1, and IRS-1 all act on the cell cycle program and/or ribosome biogenesis but that only IRS-1 can extinguish the differentiation program initiated by activated IGF-IR. In this model, IRS-1 would send three different signals: (i) an increase in cell size (63); (ii) activation of the cell cycle program (49); and (iii) extinction of the differentiation program initiated by IGF-IR (32, 61, 63). This interpretation is supported by our finding that the overexpression of PES1 or UBF1 causes the transformation of MEFs. There is indeed no question that both PES1 and UBF1 can transform 3T3-like MEFs, as the number of colonies in soft agar is quite high. MEFs have no propensity to differentiate, and PES1 and UBF1 can be transforming for these cells because they do not need to extinguish a differentiation program. It seems a sensible explanation that for 32D-derived cells that also have a differentiation program, this latter has to be blocked for sustained growth to occur.
We mentioned above that IRS-1 induces ID2 expression, which could explain simply why it blocks differentiation. ID proteins bind to pRb (20, 29), which binds to C/EBP
(8) and induces differentiation. It is possible, though, that IRS-1 has alternative pathways for inhibit diffentiation. pRb also inhibits RNA polymerase I transcription by binding and inactivating UBF1 (7, 9, 17, 18, 69), while IRS-1 binds UBF1 and activates transcription from the ribosomal DNA promoter (46, 58). Alternatively, IRS-1 could displace inhibitory pRb from UBF1. It is also possible that different pathways merge. Rockman et al. (51) reported that ß-catenin up-regulates ID2 expression, and we have found that nuclear IRS-1 interacts with ß-catenin (unpublished data).
In conclusion, our results indicate that PES1 and UBF1 cannot induce sustained cell proliferation in 32D IGF-IR cells, despite their effects on cell size and DNA replication, which allow them to transform MEFs in cultures. We propose that PES1 and UBF1 are incapable of extinguishing the differentiation program that is initiated in 32D IGF-IR cells simultaneously with the induction of the cell cycle program. Although there are other explanations, it is important to point out that IGF-IR in these cells already sends a mitogenic signal, as the cells grow vigorously for 48 h, so that the inhibition of differentiation really may be the crucial event for sustained cell proliferation. In the absence of a differentiation signal, as in MEFs, PES1 and UBF1 can transform contact-inhibited cells into cells capable of forming colonies in soft agar. This interpretation is supported by the report that c-Myc, which is required for the initiation of the cell cycle program (22), is induced by IGF-I (49). Finally, these results support the concept proposed by several investigators that a block in differentiation is an integral part of malignancies, particularly hemopoietic malignancies (14, 42, 60). Indeed, our data provide a good model for studying the molecular mechanisms that determine the outcome of differentiation and transformation in myeloid cells.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Belletti, B., M. Prisco, A. Morrione, B. Valentinis, M. Navarro, and R. Baserga. 2001. Regulation of Id2 gene expression by the IGF-I receptor requires signaling by phosphatidylinositol-3 kinase. J. Biol. Chem. 276:13867-13874.
3. Benezra, R., R. L. Davis, D. Lockshon, D. L. Turner, and H. Weintraub. 1990. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61:49-59.[CrossRef][Medline]
4. Bohni, R., J. Riesco-Escovar, S. Oldham, W. Brogiolo, H. Stocker, B. F. Andruss, K. Beckingham, and E. Hafen. 1999. Autonomous control of cell and organ size by CHICO, a Drosophila homolog of vertebrate IRS-1. Cell 97:865-875.[CrossRef][Medline]
5. Brown, G., M. T. Drayson, J. Durham, K. M. Toellner, P. J. Hughes, M. A. Choudhry, D. R. Taylor, and R. H. Michell. 2002. HL60 cells halted in G1 or S phase differentiate normally. Exp. Cell Res. 281:28-38.[CrossRef][Medline]
6. Castaigne, S., C. Chomienne, M. T. Daniel, P. Ballerini, R. Berger, P. Fenaux, and L. Degos. 1990. All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76:1704-1709.
7. Cavanaugh, A. H., W. M. Hempel, L. J. Taylor, V. Rogalsky, G. Todorov, and L. I. Rothblum. 1995. Activity of RNA polymerase I transcription factor UBF blocked by Rb gene product. Nature 374:177-180.[CrossRef][Medline]
8. Chen, P. L., D. J. Riley, Y. Chen, and L. W. Lee. 1996. Retinoblastoma protein positively regulates terminal adipocyte differentiation through direct interaction with C/EBPs. Genes Dev. 10:2794-2804.
9. Ciarmatori, S., P. H. Scott, J. E. Sutcliffe, A. McLees, H. M. Alzuherri, J. H. Dannenberg, H. Riele, L. Grummt, R. Voit, and R. J. White. 2001. Overlapping function of the pRb family in the regulation of rRNA synthesis. Mol. Cell. Biol. 21:5806-5814.
10. Comai, L., Y. Song, C. Tan, and T. Bui. 2000. Inhibition of RNA polymerase I transcription in differentiated myeloid leukemia cells by inactivation of selectivity factor-1. Cell Growth Differ. 11:63-70.
11. Datta, P. K., S. Budhiraja, R. R. Reichel, and T. J. Samson. 1997. Regulation of ribosomal RNA gene transcription during retinoic acid-induced differentiation of mouse teratocarcinoma cells. Exp. Cell Res. 231:198-205.[CrossRef][Medline]
12. Du, Y. C. N., and B. Stillman. 2002. Yph1p, an ORC-interacting protein: potential link between cell proliferation control, DNA replication and ribosome biogenesis. Cell 109:835-848.[CrossRef][Medline]
13. Fraser, R. S. S., and P. Nurse. 1978. Novel cell cycle control of RNA synthesis in yeasts. Nature 27:726-730.
14. Gilliland, D. G., and M. S. Tallman. 2002. Focus on acute leukemias. Cancer Cell 1:417-420.[CrossRef][Medline]
15. Grueneberg, D. A., L. Pablo, K. Q. Hu, P. August, Z. Weng, and J. Papkoff. 2003. A functional screen in human cells identifies UBF2 as an RNA polymerase II transcription factor that enhances the ß-catenin signaling pathway. Mol. Cell. Biol. 23:3936-3950.
16. Grummt, I. 1999. Regulation of mammalian ribosomal gene transcription by RNA polymerase I. Prog. Nucleic Acid Res. Mol. Biol. 62:109-153.
17. Hannan, K. M., R. D. Hannan, S. D. Smith, L. S. Jefferson, M. Lun, and L. I. Rothblum. 2000. Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. Oncogene 19:4988-4999.[CrossRef][Medline]
18. Hannan, K. M., B. K. Kennedy, A. H. Cavanaugh, R. D. Hannan, I. Hirschler-Laszkiewicz, L. S. Jefferson, and L. I. Rothblum. 2000. RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. Oncogene 19:3487-3497.[CrossRef][Medline]
19. Hartwell, L. H. 1978. Cell division from a genetic perspective. J. Cell Biol. 77:627-637.
20. Iavarone, A., P. Garg, A. Lasorella, J. Hsu, and M. A. Israel. 1994. The helix-loop-helix protein Id-2 enhances cell proliferation and binds to the retinoblastoma protein. Genes Dev. 8:1270-1284.
21. Iben, S., H. Tschochner, M. Bler, D. Hoogstraten, P. Hozak, J. M. Egly, and I. Grummt. 2002. TFIIH plays an essential role in RNA polymerase I transcription. Cell 109:297-306.[CrossRef][Medline]
22. Johansen, L. M., A. Iwama, T. A. Lodie, K. Sasaki, T. W. Felsher, T. R. Golub, and D. G. Tenen. 2001. c-Myc is a critical target for C/EBP
in granulopoiesis. Mol. Cell. Biol. 21:3789-3806.
23. Jorgensen, P., J. L. Nishikawa, B. J. Breitkreutz, and M. Tyers. 2002. Syst. identification of pathways that couple cell growth and division in yeast. Science 297:395-400.
24. Keeshan. K., G. Santilli, F. Corradini, D. Perrotti, and B. Calabretta. 2003. Transcription activation function of C/EBP
is required for induction of granulocytic differentiation. Blood 102:1267-1275.
25. Kim, B., P. S. Leventhal, M. F. White, and E. L. Feldman. 1998. Differential regulation of insulin receptor substrate-2 and mitogen-activated protein kinase tyrosine phosphorylation by phosphatidylinositol 3-kinase inhibitors in SH-SY5Y human neuroblastoma cells. Endocrinology 139:4881-4889.
26. Kinoshita, Y., A. D. Jarell, J. M. Flaman, G. Foltz, J. Schuster, B. L. Sopher, D. K. Irvi, H. I. Kornblum, P. S. Nelson, P. Hoieter, and R. S. Morrison. 2001. Pescadillo, a novel cell cycle regulatory protein abnormally expressed in malignant cells. J. Biol. Chem. 276:6656-6665.
27. Kreider, B. L., R. Benezra, G. Rovera, and T. Kadesch. 1992. Inhibition of myeloid differentiation by the helix-loop-helix protein Id. Science 255:1700-1702.
28. Larson, D. E., W. Q. Xie, M. Glibetic, D. O'Mahony, B. H. Sells, and L. I. Rothblum. 1993. Coordinated decrease in rRNA gene transcription factors and rRNA synthesis during muscle differentiation. Proc. Natl. Acad. Sci. USA 90:7933-7936.
29. Lasorella, A., M. Noseda, M. Beyna, and A. Iavarone. 2000. Id2 is a retinoblasoma protein target and mediates signaling by Myc oncoproteins. Nature 407:592-598.[CrossRef][Medline]
30. Leevers, S. J., D. Weinkove, L. K. MacDougall, E. Hafen, and M. D. Waterfield. 1996. The Drosophila phosphoinositide 3-kinase Dp110 promotes cell growth. EMBO J. 15:6584-6594.[Medline]
31. Lerch-Gaggl, A., J. Haque, J. Li, G. Ning, P. Traktman, and S. A. Duncan. 2002. Pescadillo is essential for nucleolar assembly, ribosome biogenesis, and mammalian cell proliferation. J. Biol. Chem. 277:45347-45355.
32. Li, Y. M., D. H. Schacher, Q. Liu, S. Arkins, N. Rebeiz, R. H. McCusker, Jr., R. Dantzer, and K. W. Kelley. 1997. Regulation of myeloid growth and differentiation by the insulin-like growth factor receptor. Endocrinology 138:362-368.
33. Lin, C. Y., J. A. Tuan, P. Scalia, T. Bul, and L. Comai. 2002. The cell cycle regulatory factor TAF1 stimulates ribosomal DNA transcription by binding to the activator UBF. Curr. Biol. 12:2142-2146.[CrossRef][Medline]
34. Liu, J.-P., J. Baker, A. S. Perkins, E. J. Robertson, and A. Efstratiadis. 1993. Mice carrying null mutations of the genes encoding insulin-like growth factor I (igf-1) and type 1 IGF receptor (Igf1r). Cell 75:59-72.[Medline]
35. Montagne, J., M. J. Stewart, H. Stocker, E. Hafen, S. C. Kozma, and G. Thomas. 1999. Drosophila 6 kinase: a regulator of cell size. Science 285:2126-2129.
36. Morrione, M., M. Navarro, G. Romano, M. Dews, K. Reiss, B. Valentinis, B. Belletti, and R. Baserga. 2001. The role of the insulin receptor substrate-1 in the differentiation of rat hippocampal neuronal cells. Oncogene 20:4842-4852.[CrossRef][Medline]
37. Moss, T., and V. Y. Stefanovsky. 1995. Promotion and regulation of ribosomal transcription in eukaryotes by RNA polymerase I. Prog. Nucleic Acids Res. Mol. Biol. 50:25-66.
38. Mueller, C., M. Alunni-Fabbroni, E. Kowenz-Leutz, X. Mo, M. Tommasino, and A. Leutz. 1999. Separation of C/EBP
-mediated proliferation arrest and differentiation pathways. Proc. Natl. Acad. Sci. USA 96:7276-7281.
39. Navarro, M., and R. Baserga. 2001. Limited redundancy of survival signals from the type 1 insulin-like growth factor receptor. Endocrinology 142:1073-1081.
40. Navarro, M., B. Valentinis, B. Belletti, G. Romano, K. Reiss, and R. Baserga. 2001. Regulation of Id2 gene expression by the type 1 IGF receptor and the insulin receptor substrate-1. Endocrinology 142:5149-5157.
41. O'Brien, T., and R. Tjian. 2000. Different functional domains of TAFII250 modulate expression of distinct subsets of mammalian genes. Proc. Natl. Acad. Sci. USA 97:2456-2461.
42. Pabst, T., B. U. Mueller, P. Zhang, H. S. Radomska, S. Narravula, S. Schnittger, G. Behre, W. Hiddemann, and D. G. Tenen. 2001. Dominant negative mutations of CEBP
, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat. Genet. 27:263-270.[CrossRef][Medline]
43. Perrotti, D., V. Cesi, R. Trotta, C. Guerzoni, G. Santilli, K. Campbell, A. Iervolino, F. Condorelli, C. Gambacorti-Passerini, M. A. Caligiuri, and B. Calabretta. 2001. BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2. Nat. Genet. 30:48-58.
44. Peruzzi, F., M. Prisco, M. Dews, P. Salomoni, E. Grassilli, G. Romano, B. Calabretta, and R. Baserga. 1999. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol. Cell. Biol. 19:7203-7215.
45. Pete, G., G. R. Fuller, J. M. Oldham, D. R. Smith, A. J. D'Ercole, C. R. Kahn, and P. K. Lund. 1999. postnatal growth responses to insulin-like growth factor 1 in insulin receptor substrate-1 mice. Endocrinology 140:5478-5487.
46. Prisco, M., F. Santini, R. Baffa, M. Liu, R. Drakas, A. Wu, and R. Baserga. 2002. Nuclear translocation of IRS-1 by the SV40 T antigen and the activated IGF-I receptor. J. Biol. Chem. 277:32078-32085.
47. Prisco, M., F. Peruzzi, B. Belletti, and R. Baserga. 2001. Regulation of Id gene expression by the type 1 insulin-like growth factor: roles of Stat3 and the tyrosine 950 residue of the receptor. Mol. Cell. Biol. 21:5447-5458.
48. Reeder, R. H. 1999. Regulation of RNA polymerase transcription in yeast and vertebrates. Prog. Nucleic Acid Res. Mol. Biol. 62:293-327.
49. Reiss, K., B. Valentinis, X. Tu, S. Q. Xu, and R. Baserga. 1998. Molecular markers of IGF-I-mediated mitogenesis. Exp. Cell Res. 242:361-372.[CrossRef][Medline]
50. Ringertz, N. R., and R. E. Savage. 1976. Cell hybrids. Academic Press, Inc., New York, N.Y.
51. Rockman, S. P., S. A. Currie, M. Ciavarella, E. Vincan, C. Dow, R. J. S. Thomas, and W. A. Phillips. 2001. Id2 is a target of the ß-catenin/T cell factor pathway in colon carcinoma. J. Biol. Chem. 276:45113-45119.
52. Rubini, M., A. Hongo, C. D'Ambrosio, and R. Baserga. 1997. The IGF-I receptor in mitogenesis and transformation of mouse embryo cells: role of receptor number. Exp. Cell Res. 230:284-292.[CrossRef][Medline]
53. Sadowski, C. L., T. S. Choi, M. Le, T. T. Wheeler, L. H. Wang, and H. B. Sadowski. 2001. Insulin induction of SOCS-2 and SOCS-3 mRNA expression in C2C12 skeletal muscle cells is mediated by Stat5. J. Biol. Chem. 276:20703-20710.
54. Sawyers, C. L., C. T. Denny, and O. N. Witte. 1991. Leukemia and the disruption of normal hematopoiesis. Cell 64:337-350.[CrossRef][Medline]
55. Sciacca, L., M. Prisco, A. Wu, A. Belfiore, R. Vigneri, and R. Baserga. 2003. Signaling differences from the A and B isoforms of the insulin receptor (IR) in 32D cells in the preence or absence of IR substrate-1. Endocrinology 144:2650-2658.
56. Sell, C., M. Rubini, R. Rubin, J.-P. Liu, A. Efstratiadis, and R. Baserga. 1993. Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type-1 IGF receptor. Proc. Natl. Acad. Sci. USA 90:11217-11221.
57. Shima, H., M. Pende, Y. Chen, S. Fumagalli, G. Thomas, and S. C. Kozma. 1998. Disruption of the p70S6K/p85S6K gene reveals a small mouse phenotype and a new functional S6 kinase. EMBO J. 17:6649-6659.[CrossRef][Medline]
58. Sun, H., X. Tu, M. Prisco, A. Wu, I. Casiburi, and R. Baserga. 2003. Insulin-like growth factor I receptor signaling and nuclear translocation of insulin receptor substrates 1 and 2. Mol. Endocrinol. 17:472-486.
59. Sun, X. J., S. Pons, L. M. Wang, Y. Zhang, L. Yenush, D. Burks, M. G. Myers, Jr., E. Glasheen, N. G. Copeland, N. A. Jenkins, and M. F. White. 1997. The IRS-2 gene on murine chromosome 8 encodes a unique signaling adapter for insulin and cytokine action. Mol. Endocrinol. 11:251-262.
60. Tenen, D. G. 2001. Abnormalities of CEBP alpha transcription factor: a major target in acute myeloid leukemia. Leukemia 15:688-689.[CrossRef][Medline]
61. Tu, X., R. Baffa, S. Luke, M. Prisco, and R. Baserga. 2003. Intracellular redistribution of nuclear and nucleolar proteins during differentiation of 32D murine hemopoietic cells. Exp. Cell Res. 288:119-130.[CrossRef][Medline]
62. Tu, X., P. Batta, N. Innocent, M. Prisco, I. Casaburi, B. Belletti, and R. Baserga. 2002. Nuclear translocation of insulin receptor substrate-1 by oncogenes and IGF-I: effect on ribosomal RNA synthesis. J. Biol. Chem. 277:44357-44365.
63. Valentinis, B., M. Navarro, T. Zanocco-Marani, P. Edmonds, J. McCormick, A. Morrione, A. Sacchi, G. Romano, K. Reiss, and R. Baserga. 2000. Insulin receptor substrate-1, p70S6K and cell size in transformation and differentiation of hemopoietic cells. J. Biol. Chem. 275:25451-25459.
64. Valentinis, B., G. Romano, F. Peruzzi, A. Morrione, M. Prisco, S. Soddu, B. Cristofanelli, A. Sacchi, and R. Baserga. 1999. Growth and differentiation signals by the insulin-like growth factor 1 receptor in hemopoietic cells are mediated through different pathways. J. Biol. Chem. 274:12423-12430.
65. Valtieri, M., D. J. Tweardy, D. Caracciolo, K. Johnson, F. Mavilio, S. Altmann, D. Santoli, and G. Rovera. 1987. Cytokine dependent granulocytic differentiation. J. Immunol. 138:3829-3835.[Abstract]
66. Verdu, J., M. A. Buratovich, E. L. Wilder, and M. J. Birnbaum. 1999. Cell-autonomous regulation of cell and organ growth in Drosophila by Akt/PKB. Nat. Cell Biol. 1:500-506.[CrossRef][Medline]
67. Voit, R., M. Hoffmann, and I. Grummt. 1999. Phosphorylation of G1-specific cdk-cyclin complexes activates the nucleolar transcription factor UBF. EMBO J. 18:1891-1899.[CrossRef][Medline]
68. Voit, R., A. Kuhn E. E. Sander, and I. Grummt. 1995. Activation of mammalian ribosomal gene transcription requires phosphorylation of the nucleolar transcription factor UBF. Nucleic Acids Res. 23:2593-2599.
69. Voit, R., K. Schafer, and I. Grummt. 1997. Mechanism of repression of RNA polymerase I transcription by the retinoblastoma protein. Mol. Cell. Biol. 17:4230-4237.[Abstract]
70. Wang, L. M., M. G. Myers, Jr., X. J. Sun, S. A. Aaronson, M. White, and J. H. Pierce. 1993. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hemopoietic cells. Science 261:1591-1594.
71. Ward, A. C., L. Smith, J. P. de Koning, Y. van Aesch, and I. P. Touw. 1999. Multiple signals mediate proliferation, differentiation and survival from the granulocyte-colony stimulating factor receptor in myeloid 32D cells. J. Biol. Chem. 274:14956-14962.
72. White, M. F. 1998. The IRS-signalling system: a network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 182:3-11.[CrossRef][Medline]
73. Zamorano, J., H. Y. Wang, L.-M., Wang, J. H. Pierce, and A. D.